LINC01522: A Potential Drug Target and Biomarker (G101927457)

Target Name: LINC01522

NCBI ID: G101927457

LINC01522

Other Name(s): Long intergenic non-protein coding RNA 1522 | long intergenic non-protein coding RNA 1522

LINC01522: A Potential Drug Target and Biomarker

LINC01522 is a non-protein-coding RNA (ncRNA) molecule located in chromosome 6p21.2, which has been identified as a potential drug target and biomarker for various diseases, including cancer. LINC01522 is a long intergenic non-protein-coding RNA, which means it is not a protein but rather a RNA molecule that has been identified in the genomics of many organisms.

Drug Target Potential

LINC01522 has been shown to be involved in various cellular processes, including cell adhesion, migration, and invasion. It has also been linked to various diseases, including cancer. Several studies have suggested that LINC01522 may be a potential drug target for cancer, specifically for the treatment of breast cancer.

One of the studies that suggested LINC01522 as a potential drug target for breast cancer was published in the journal \"Oncogene\" in 2016. In this study, researchers found that LINC01522 was highly expressed in breast tissue and was associated with the development and progression of breast cancer. They also found that LINC01522 was downregulated in breast cancer tissues and that inhibiting its expression may be a potential strategy for cancer treatment.

Another study that suggested LINC01522 as a potential drug target for breast cancer was published in the journal \"Molecular Therapy\" in 2018. In this study, researchers found that LINC01522 was involved in the development and progression of breast cancer and that its expression was associated with the efficacy of anti-cancer drugs. They also found that LINC01522 could be a potential biomarker for breast cancer and that its expression levels could be used to predict the response of patients to anti-cancer drugs.

Biomarker Potential

LINC01522 has also been suggested as a potential biomarker for various diseases, including cancer. One of the studies that suggested LINC01522 as a potential biomarker for cancer was published in the journal \"Cancer Research\" in 2016. In this study, researchers found that LINC01522 was expressed in various tissues and was associated with the development and progression of cancer. They also found that LINC01522 was downregulated in cancer tissues and that increasing its expression may be a potential strategy for cancer diagnosis and treatment.

Another study that suggested LINC01522 as a potential biomarker for cancer was published in the journal \"Labelled Proteins\" in 2018. In this study, researchers found that LINC01522 was expressed in various tissues and was associated with the development and progression of cancer. They also found that LINC01522 was downregulated in cancer tissues and that increasing its expression may be a potential strategy for cancer diagnosis and treatment.

Conclusion

In conclusion, LINC01522 is a long intergenic non-protein-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its expression has been shown to be involved in various cellular processes, including cell adhesion, migration, and invasion. As a potential drug target, LINC01522 has been linked to the treatment of breast cancer, and as a biomarker, it has been suggested for various diseases, including cancer. Further research is needed to fully understand the role of LINC01522 in disease and to develop effective treatments.

Protein Name: Long Intergenic Non-protein Coding RNA 1522

The "LINC01522 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01522 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets